HRP20180180T1 - Derivat polimiksina i njegova uporaba - Google Patents
Derivat polimiksina i njegova uporaba Download PDFInfo
- Publication number
- HRP20180180T1 HRP20180180T1 HRP20180180TT HRP20180180T HRP20180180T1 HR P20180180 T1 HRP20180180 T1 HR P20180180T1 HR P20180180T T HRP20180180T T HR P20180180TT HR P20180180 T HRP20180180 T HR P20180180T HR P20180180 T1 HRP20180180 T1 HR P20180180T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutical preparation
- dab
- pharmaceutically acceptable
- preparation according
- Prior art date
Links
- 108010040201 Polymyxins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- -1 fluoroketolides Chemical compound 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 2
- 108010034396 Streptogramins Proteins 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229960002626 clarithromycin Drugs 0.000 claims 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 2
- 229960002227 clindamycin Drugs 0.000 claims 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 2
- 229960002488 dalbavancin Drugs 0.000 claims 2
- 108700009376 dalbavancin Proteins 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 2
- 229940124307 fluoroquinolone Drugs 0.000 claims 2
- 229940014144 folate Drugs 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 229960004675 fusidic acid Drugs 0.000 claims 2
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 2
- 229960003128 mupirocin Drugs 0.000 claims 2
- 229930187697 mupirocin Natural products 0.000 claims 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 2
- 229960001607 oritavancin Drugs 0.000 claims 2
- 108010006945 oritavancin Proteins 0.000 claims 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims 2
- 229960000885 rifabutin Drugs 0.000 claims 2
- 229950005007 rifalazil Drugs 0.000 claims 2
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 2
- 229960005240 telavancin Drugs 0.000 claims 2
- 108010089019 telavancin Proteins 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims 2
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 claims 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 1
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000588919 Citrobacter freundii Species 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 1
- 125000000197 D-threonyl group Chemical group N[C@@H](C(=O)*)[C@H](C)O 0.000 claims 1
- 241000588697 Enterobacter cloacae Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000588749 Klebsiella oxytoca Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 229960003071 bacitracin Drugs 0.000 claims 1
- 229930184125 bacitracin Natural products 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 claims 1
- HLFSMUUOKPBTSM-ISIOAQNYSA-N chembl1951095 Chemical compound C([C@H]1C[C@H]2[C@@H](C(=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C1C(=O)C1=C2O)O)N(C)C)C1=C(F)C=C2NC(=O)CN1CCCC1 HLFSMUUOKPBTSM-ISIOAQNYSA-N 0.000 claims 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 claims 1
- 229950006412 delafloxacin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950004877 eravacycline Drugs 0.000 claims 1
- 239000003835 ketolide antibiotic agent Substances 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- 229960002950 novobiocin Drugs 0.000 claims 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 229950004150 omadacycline Drugs 0.000 claims 1
- JEECQCWWSTZDCK-IQZGDKDPSA-N omadacycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JEECQCWWSTZDCK-IQZGDKDPSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 claims 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 1
- 229940081192 rifamycins Drugs 0.000 claims 1
- 229950008588 solithromycin Drugs 0.000 claims 1
- 229940041030 streptogramins Drugs 0.000 claims 1
- 229960003879 tedizolid Drugs 0.000 claims 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- 229960001082 trimethoprim Drugs 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1. Spoj s općom formulom (I),
[image]
naznačen time da
R1 je Dab
R2 je Thr
R3 je DThr
R4 je Dab
R5 je Dab
R6 je DPhe
R7 je Leu
R8 je Abu
R9 je Dab;
R10 je Thr; i
R(FA) je oktanoil;
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja ili njegove farmaceutski prihvatljive soli kako je zatraženo u zahtjevu 1 i najmanje jedan farmaceutski prihvatljiv nosač i/ili ekscipijent.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time da dodatno sadrži jedan ili više drugih aktivnih sastojaka.
4. Farmaceutski pripravak prema zahtjevu 3, naznačen time da navedeni drugi aktivni sastojak je antibakterijsko sredstvo odabrano iz skupine koju čine klaritromicin, azitromicin, eritromicin i drugi makrolidi, ketolidi, fluoroketolidi, klindamicin i drugih linkozamini, streptogramini, rifampin, rifabutin, rifalazil i drugih rifamicini, fusidna kiselina, mupirocin, oksazolidinoni, vankomicin, dalbavancin, telavancin, oritavancin i drugi glikopeptidni antibiotici, fluorokinoloni, bacitracin, tetraciklin i derivati fluorociklina, betalaktamski antibiotici, novobiocin, pleuromutilini, inhibitori sinteze folata, inhibitori deformilaze, inhibitori bakterijske efluksne pumpe.
5. Farmaceutski pripravak prema zahtjevu 4, naznačen time da je navedeno antibakterijsko sredstvo odabrano iz skupine koju čine: klaritromicin, azitromicin, eritromicin, telitromicin, solitromicin, klindamicin, kombinacija streptogramina kinupristin-dalfopristin, eravaciklin, minociklin, omadaciklin, rifampin, rifabutin, rifalazil, fusidna kiselina, mupirocin, oksazolidinoni tedizolid i linezolid, vankomicin, dalbavancin, oritavancin, telavancin, fluorokinoloni moksifloksacin, delafloksacin i avarafloksacin, te inhibitor sinteze folata trimetoprim.
6. Spoj kako je zatraženo u zahtjevu 1, ili farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, naznačen time da je za uporabu kao lijek.
7. Spoj kako je zatraženo u zahtjevu 1, ili farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, naznačen time da je za uporabu za liječenje bakterijske infekcije.
8. Spoj kako je zatraženo u zahtjevu 1, ili farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, za uporabu prema zahtjevu 7, naznačen time da bakterija je gram negativna bakterija.
9. Spoj kako je zatraženo u zahtjevu 1, ili farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 5, za uporabu prema zahtjevu 7, naznačen time da su navedene bakterije odabrane iz skupine koju čine: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii, Pseudomonas aeruginosa, i Acinetobacter baumannii.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20155027A FI126143B (en) | 2015-01-15 | 2015-01-15 | Polymyxine derivative and its uses |
| EP16151398.1A EP3045469B1 (en) | 2015-01-15 | 2016-01-15 | Polymyxin derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180180T1 true HRP20180180T1 (hr) | 2018-03-09 |
Family
ID=55310836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180180TT HRP20180180T1 (hr) | 2015-01-15 | 2018-01-31 | Derivat polimiksina i njegova uporaba |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3045469B1 (hr) |
| JP (1) | JP6471236B2 (hr) |
| KR (1) | KR102020886B1 (hr) |
| CN (1) | CN107207569B (hr) |
| AU (1) | AU2016207942B2 (hr) |
| CA (1) | CA2972743C (hr) |
| DK (1) | DK3045469T3 (hr) |
| ES (1) | ES2656562T3 (hr) |
| FI (1) | FI126143B (hr) |
| HR (1) | HRP20180180T1 (hr) |
| HU (1) | HUE035778T2 (hr) |
| IL (1) | IL253457B (hr) |
| MX (1) | MX2017009094A (hr) |
| NO (1) | NO3045469T3 (hr) |
| PT (1) | PT3045469T (hr) |
| RU (1) | RU2675819C1 (hr) |
| SG (1) | SG11201705125UA (hr) |
| TW (1) | TWI694087B (hr) |
| WO (1) | WO2016113470A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556769B1 (en) * | 2016-12-16 | 2023-06-14 | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences | Polymyxin derivative, preparation method and application thereof |
| GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
| GB201704620D0 (en) | 2017-03-23 | 2017-05-10 | Helperby Therapeautics Ltd | Combinations |
| CN107661349A (zh) * | 2017-11-24 | 2018-02-06 | 刘晓峰 | 一种治疗小儿高热的联合用药物 |
| CN110179967A (zh) * | 2019-05-28 | 2019-08-30 | 中国医药集团总公司四川抗菌素工业研究所 | 多粘菌素母核和一种抗生素的组合物及其应用 |
| IT201900025414A1 (it) | 2019-12-23 | 2021-06-23 | Univ Bologna Alma Mater Studiorum | Composto per il trattamento della sindrome emolitico uremica |
| WO2022206826A1 (zh) * | 2021-03-31 | 2022-10-06 | 江苏奥赛康药业有限公司 | 一种多粘菌素衍生物的硫酸盐及其药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754411A (fr) * | 1969-08-05 | 1971-02-04 | Rhone Poulenc Sa | Cyclopeptides derives des polymyxines et leur |
| TW274552B (hr) * | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| HUE028271T2 (en) * | 2006-08-11 | 2016-12-28 | Northern Antibiotics Oy | Polymixin derivatives and their applications |
| US7807637B2 (en) | 2006-08-11 | 2010-10-05 | Northern Antibiotics Oy | Polymyxin derivatives and uses thereof |
| FI20085469A0 (fi) * | 2008-02-08 | 2008-05-16 | Northern Antibiotics Oy | Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä |
| EP2780357A1 (en) | 2011-11-18 | 2014-09-24 | Novacta Biosystems Limited | Polymyxin derivatives |
| KR20150107793A (ko) * | 2013-01-11 | 2015-09-23 | 셀리아 파마슈티칼즈 에이피에스 | 폴리믹신, 조성물, 제조 방법 및 사용 방법 |
| WO2014188178A1 (en) | 2013-05-22 | 2014-11-27 | Cantab Anti-Infectives Limited | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
-
2015
- 2015-01-15 FI FI20155027A patent/FI126143B/en active IP Right Grant
-
2016
- 2016-01-15 HU HUE16151398A patent/HUE035778T2/hu unknown
- 2016-01-15 EP EP16151398.1A patent/EP3045469B1/en active Active
- 2016-01-15 SG SG11201705125UA patent/SG11201705125UA/en unknown
- 2016-01-15 NO NO16151398A patent/NO3045469T3/no unknown
- 2016-01-15 WO PCT/FI2016/050016 patent/WO2016113470A1/en active Application Filing
- 2016-01-15 RU RU2017127011A patent/RU2675819C1/ru active
- 2016-01-15 ES ES16151398.1T patent/ES2656562T3/es active Active
- 2016-01-15 JP JP2017536921A patent/JP6471236B2/ja active Active
- 2016-01-15 CA CA2972743A patent/CA2972743C/en active Active
- 2016-01-15 DK DK16151398.1T patent/DK3045469T3/en active
- 2016-01-15 PT PT161513981T patent/PT3045469T/pt unknown
- 2016-01-15 KR KR1020177022255A patent/KR102020886B1/ko active IP Right Grant
- 2016-01-15 AU AU2016207942A patent/AU2016207942B2/en not_active Ceased
- 2016-01-15 MX MX2017009094A patent/MX2017009094A/es active IP Right Grant
- 2016-01-15 TW TW105101251A patent/TWI694087B/zh active
- 2016-01-15 CN CN201680005506.9A patent/CN107207569B/zh active Active
-
2017
- 2017-07-12 IL IL25345717A patent/IL253457B/en active IP Right Grant
-
2018
- 2018-01-31 HR HRP20180180TT patent/HRP20180180T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2656562T3 (es) | 2018-02-27 |
| CN107207569A (zh) | 2017-09-26 |
| IL253457A0 (en) | 2017-09-28 |
| PT3045469T (pt) | 2018-02-08 |
| TW201630930A (zh) | 2016-09-01 |
| EP3045469B1 (en) | 2017-11-29 |
| JP2018505868A (ja) | 2018-03-01 |
| TWI694087B (zh) | 2020-05-21 |
| IL253457B (en) | 2019-10-31 |
| CA2972743A1 (en) | 2016-07-21 |
| BR112017014670A2 (pt) | 2018-03-13 |
| AU2016207942A1 (en) | 2017-08-10 |
| EP3045469A1 (en) | 2016-07-20 |
| NO3045469T3 (hr) | 2018-04-28 |
| JP6471236B2 (ja) | 2019-02-13 |
| KR20170102005A (ko) | 2017-09-06 |
| SG11201705125UA (en) | 2017-07-28 |
| AU2016207942B2 (en) | 2018-05-10 |
| FI20155027A (fi) | 2016-07-15 |
| MX2017009094A (es) | 2018-03-01 |
| KR102020886B1 (ko) | 2019-09-16 |
| FI126143B (en) | 2016-07-15 |
| WO2016113470A1 (en) | 2016-07-21 |
| HUE035778T2 (hu) | 2018-08-28 |
| DK3045469T3 (en) | 2018-03-05 |
| RU2675819C1 (ru) | 2018-12-25 |
| CN107207569B (zh) | 2020-11-03 |
| CA2972743C (en) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180180T1 (hr) | Derivat polimiksina i njegova uporaba | |
| HRP20160552T1 (hr) | Derivati polimiksina i njihove uporabe | |
| Rai et al. | Recent advances in antibacterial drugs | |
| CN102319246B (zh) | 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物 | |
| KR100900208B1 (ko) | 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물 | |
| IN2014DN08939A (hr) | ||
| HRP20130928T1 (hr) | C7-fluor supstituirani spojevi tetraciklina | |
| RU2014134720A (ru) | Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения | |
| CA3143793C (en) | Biofilm disruption | |
| Arias et al. | Activity of bone cement loaded with daptomycin alone or in combination with gentamicin or PEG600 against Staphylococcus epidermidis biofilms | |
| JP2008540515A (ja) | 嚢胞性線維症を含む重症感染症の処置および管理 | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| JP2018500387A5 (hr) | ||
| AU2007279442A2 (en) | Antibiotic composition | |
| Bosso | The antimicrobial armamentarium: evaluating current and future treatment options | |
| JP2018503688A (ja) | 感染症を患う被験体における抗感染症療法の期間を短縮する方法 | |
| WO2013042140A2 (en) | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement | |
| Strahilevitz et al. | Novel agents for resistant Gram-positive infections—a review | |
| JP2018521143A5 (hr) | ||
| Kajihara et al. | Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis | |
| ES2377016T3 (es) | Tioridazina y derivados de la misma para invertir la resistencia a los fármacos anti-microbianos | |
| WO2017019943A1 (en) | Antimicrobial formulations and applications thereof | |
| JP6178224B2 (ja) | 併用抗メチシリン耐性黄色ブドウ球菌薬、及びβラクタム系抗生物質の抗菌活性増強剤 | |
| EP4429651A1 (en) | Methods for biofilm disruption | |
| UA94177C2 (en) | antimicrobial composition |